The landscape of liver disease management has been transformed by direct-acting antiviral (DAA) therapies that cure hepatitis C in more than 95% of treated patients, and by expanding non-alcoholic fatty liver disease (NAFLD) — now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD) — surveillance programs. Yet for gastroenterology and hepatology practices, these clinical advances have created substantial administrative complexity that most front-office teams were not built to handle.
The Hepatitis C Treatment Authorization Challenge
The American Association for the Study of Liver Diseases (AASLD) estimates that approximately 2.4 million Americans are living with chronic hepatitis C, with hundreds of thousands remaining untreated due to access barriers. DAA regimens — including sofosbuvir/velpatasvir (Epclusa), glecaprevir/pibrentasvir (Mavyret), and ledipasvir/sofosbuvir (Harvoni) — are highly effective but require prior authorizations that vary significantly by payer, state Medicaid program, and fibrosis stage requirements.
Many payers still impose fibrosis staging requirements — demanding documentation of at least F2 fibrosis or above — before approving DAA therapy for Medicaid patients, despite AASLD's pan-genotypic treatment guidance recommending treatment regardless of fibrosis stage. A virtual assistant managing the hepatitis C program tracks each patient's authorization status, gathers the required genotype reports, fibrosis staging results, and prescriber attestations, and submits authorization packets to specialty pharmacy hubs like AbbVie's FoundationAssist or Gilead's Advancing Access program.
When payer denials are issued, the VA prepares appeal letters citing AASLD practice guidelines and clinical necessity documentation, ensuring that appeals are filed within the window and escalated to physician review only when clinical judgment is required.
Fibroscan Scheduling and Non-Invasive Fibrosis Assessment
Transient elastography (Fibroscan) has largely replaced liver biopsy for fibrosis staging in many liver disease programs, but scheduling and result routing for these studies requires coordination that falls through the cracks when handled by a general front desk. For practices with their own Fibroscan unit, the VA manages a scheduling queue that prioritizes patients based on surveillance interval, new hepatitis C treatment workups, and MASLD monitoring protocols.
For practices that refer Fibroscan studies to hospital radiology or GI procedure centers, the VA manages referral submission, prior authorization (required by many payers), appointment confirmation, and result receipt and routing to the ordering provider. The American College of Gastroenterology (ACG) recommends serial Fibroscan assessment for MASLD patients with risk factors for progression — creating ongoing scheduling demand that benefits from systematic VA management.
MASLD/NAFLD Surveillance Coordination
With MASLD now recognized as the most common cause of chronic liver disease globally, gastroenterology practices are managing large surveillance cohorts that require recall scheduling, lab monitoring, and dietary/lifestyle documentation. A virtual assistant manages MASLD recall lists — identifying patients who are overdue for liver enzyme panels, imaging surveillance, or hepatocellular carcinoma screening — and coordinates outreach to bring them back into the monitoring cycle.
The VA also manages referral communication with endocrinology and metabolic medicine for patients with co-existing diabetes and metabolic syndrome, routing clinical summaries and coordinating shared care plans. When new pharmacological treatments for MASLD — including resmetirom (Rezdiffra), the first FDA-approved treatment for NASH-related fibrosis — require prior authorization, the VA handles the submission process including liver histology documentation requirements.
Specialty Pharmacy Coordination
Hepatitis C therapy involves close collaboration with specialty pharmacies that manage drug dispensing, patient assistance enrollment, and refill coordination. A virtual assistant serves as the practice's primary contact with the specialty pharmacy — confirming prescription receipt, tracking prior authorization approval transmission, and communicating refill timing to patients. This reduces the gaps between treatment initiation approval and actual prescription dispensing that commonly delay DAA therapy starts.
For liver disease practices managing a growing patient population and limited administrative bandwidth, Stealth Agents provides virtual assistants trained in hepatology-specific workflows including DAA prior authorization and Fibroscan coordination.
Sources
- American Association for the Study of Liver Diseases (AASLD). "HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C." hcvguidelines.org
- American College of Gastroenterology (ACG). "NAFLD/MASLD Practice Guidance." gi.org
- U.S. Food & Drug Administration (FDA). "Rezdiffra (Resmetirom) Approval." fda.gov